drug_type
RELEVANT_DRUG
intervention_type
cell therapy (genetically modified T cells)
drug_description
Genetically modified autologous T cells engineered to express an HLA-A2–restricted T-cell receptor specific for NY-ESO-1, enabling recognition and cytotoxic killing of NY-ESO-1–expressing tumor cells.
nci_thesaurus_concept_id
C122679
nci_thesaurus_preferred_term
Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes
nci_thesaurus_definition
Autologous human peripheral blood T-lymphocytes transduced with a lentiviral or retroviral vector encoding a human leukocyte antigen A2 (HLA-A2) restricted anti-cancer-testis antigen 1 (NY-ESO-1) T-cell receptor (TCR) gene, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and re-introduction into the patient, the anti-HLA-A2/NY-ESO-1 TCR-transduced autologous T lymphocytes recognize and bind to NY-ESO-1/HLA-A2-positive tumor cells. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types.
drug_mesh_term
T-Lymphocytes, Transgenic
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T lymphocytes genetically modified to express an HLA-A2-restricted T-cell receptor specific for NY-ESO-1. These TCR-T cells recognize NY-ESO-1 peptide presented by HLA-A2 on tumor cells and, upon TCR engagement, activate cytotoxic effector functions (perforin/granzyme and cytokine release) to kill NY-ESO-1-positive cancer cells.
drug_name
Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes
nct_id_drug_ref
NCT05989828